Ascendis Pharma A/S (ASND) Q3 2018 Earnings Results

Ascendis Pharma Misses on EPS, Stock Up 4.89%

Ascendis Pharma reported a loss of $0.91 per share, but the stock still rose by nearly 5%. The increase in stock price may reflect investor optimism despite the lack of revenue data and guidance. The market appears to be reacting positively to the overall sentiment around the company's future prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.91	N/A	—
Revenue	—	N/A	—

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Ascendis Pharma Misses on EPS, Stock Up 4.89%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma Misses on EPS, Stock Up 4.89%

Key numbers

Management commentary